Agenus Inc. Stock
€0.41
Your prediction
Description Agenus
Agenus Inc. (AGEN) is a biotechnology company that focuses on the development and commercialization of immuno-oncology therapeutics for the treatment of cancer. The company's pipeline includes a range of checkpoint modulators, vaccines, and adjuvants designed to activate immune response mechanisms against cancer.
The company’s products include Prophage series of cancer vaccines, Oncophage, Agenus CPM Series vaccine adjuvants, QS-21 Stimulon adjuvant, and AS-15 Immunologic adjuvant, among others.
Agenus was founded in 1994 and is headquartered in Lexington, Massachusetts. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN. Its market capitalization, as of September 2021, was approximately $1.9 billion.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Agenus
sharewise wants to provide you with the best news and tools for Agenus, so we directly link to the best financial data sources.
Financials
News
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q1 2024 Earnings CallMay 07, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Last Friday, Agenus (NASDAQ: AGEN), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to
Down 75%. Is Agenus Stock a Buy on the Dip?
The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.
Investment bank analysts on Wall Street who
Agenus (AGEN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q4 2023 Earnings CallMar 14, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (NASDAQ: AGEN)